RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Radiopharm Theranostics Ltd
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Sep 30, 2026
$0.96−0.07 (-6.50%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2022 to 2025
Gross margin
1.1%
Operating margin
-1050.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +1114.3% | – | – | – | |
| Gross profit | -86.9% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2022 | FY2022 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | – | 2.67 | |
| Interest coverage | – | – | -584.6× | |
| Diluted shares | – | – | 2.08B |
Cash use needs five years of cash flow figures
Radiopharm Theranostics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 4 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$36.65M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$36.65M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.30 → 2.67
- No dilutionShare count did not rise386M → 2.08B
- Gross margin improvedGross margin up on the prior year100.00% → 1.08%
- More efficientAsset turnover rose– → 0.05